|Year : 2019 | Volume
| Issue : 3 | Page : 923-928
Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran
Roya Mansour-Ghanaei1, Fariborz Mansour-Ghanaei1, Mohammadreza Naghipour2, Farahnaz Joukar1
1 Department of Gastroenterology, Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht, Iran
2 Department of Social Medicine, Caspian Digestive Disease Research Center, Guilan University of Medical Sciences, Rasht, Iran
|Date of Web Publication||27-Mar-2019|
Dr. Fariborz Mansour-Ghanaei
Department of Gastroenterology, M.D, AGAF, Gastrointestinal and Liver Diseases Research Center, Guilan University of Medical Sciences, Rasht
Dr. Mohammadreza Naghipour
Department of Social Medicine, Caspian Digestive Disease Research Center, Guilan University of Medical Sciences, Rasht
Source of Support: None, Conflict of Interest: None
Background and Aim: Nonalcoholic fatty liver disease (NAFLD) is a global epidemic that is often asymptomatic and silent, and progresses slowly. This study aimed to determine the biochemical markers and lipid profile among NAFLD patients and their possible relationship with degrees of fatty liver. Methods: This is analytical cross-sectional study, in which, 950 individuals referred to the PERSIAN Guilan cohort study were included through sequential sampling method. The demographic information and blood pressure of the subjects were taken and the blood sample was prepared to investigate the biochemical markers and lipid profile. Also, abdominal ultrasonography was performed to investigate NAFLD and its grades. For data analysis, independent sample t-test, one-way ANOVA, and logistic regression model were used, where P < 0.05 was considered significant. Results: The systolic blood pressure (SBP) (P < 0.001), diastolic blood pressure (DBP) (P < 0.001), hepatic enzymes (aspartate aminotransferase [AST], P < 0.001, alanine aminotransferase [ALT], P < 0.001; gamma-glutamyle transferase [GGT], P < 0.001; AST/ALT ratio, P < 0.001), lipid profile (triglyceride [TG], P < 0.001; total cholesterol [TC], P = 0.008; high density lipoprotein [HDL], P < 0.001; LDL-C/HDL-C (ratio), P = 0.003; TC/HDL-C (ratio), P < 0.001); and fasting blood sugar [FBS], P < 0.001 correlated with NAFLD. However, there was no relationship between age (P = 0.34), alkaline phosphatase [ALP] (P = 0.26) and low-density lipoprotein [LDL] (P = 0.72). Further, a significant relationship was observed between AST (P < 0.001), ALT (P < 0.001), and GGT (P = 0.004) and NAFLD degrees based on the ultrasonography. Conclusion: Biochemical markers and lipid profile are associated with NAFLD. Thus, it is recommended to investigate NAFLD in clinical settings in cases in which their changes are observed in patients through ultrasonography.
Keywords: Biochemical markers, lipid profile, nonalcoholic fatty liver disease
|How to cite this article:|
Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F. Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. J Family Med Prim Care 2019;8:923-8
|How to cite this URL:|
Mansour-Ghanaei R, Mansour-Ghanaei F, Naghipour M, Joukar F. Biochemical markers and lipid profile in nonalcoholic fatty liver disease patients in the PERSIAN Guilan cohort study (PGCS), Iran. J Family Med Prim Care [serial online] 2019 [cited 2020 Nov 27];8:923-8. Available from: https://www.jfmpc.com/text.asp?2019/8/3/923/254868
| Introduction|| |
Nonalcoholic fatty liver disease (NAFLD) is a global epidemic which is mostly asymptomatic and progresses slowly. NAFLD involves a whole spectrum of liver pathologies from simple steatosis to non-alcoholic steatohepatitis (NASH), advanced fibrosis, cirrhosis, and hepatocellular carcinoma (HCC).
Prevalence of NAFLD has doubled over the past 20 years, while prevalence of other chronic diseases of the liver has remained constant and even diminished. Prevalence of NAFLD in the world is about 25%, in non-obese Asian-Pacific individuals, it is 15–21%, in American adults, it is 30%, and in Italy, it has been reported to be 25%. In the Iranian general population, prevalence of NAFLD and NASH ranges between 2.9 and 7.1%, and in the south of Iran, it has been reported as 21.5%. Also, a systematic review studies reported a prevalence of 33.95% for NAFLD in Iran.
NAFLD is identified by abnormal liver tests, imaging studies, and liver biopsy, and has the potential to become the most common cause of liver transplantation in the future. Ultrasonography of the liver is the most common technique for screening fatty liver in the general population.
One of the common reasons for patients' visit to gastroenterology or hepatology clinics is the high levels of aminotransferase tests. Thus, currently, special attention is paid to transaminase values and in many studies, NAFLD diagnosis is based on abnormal aspartame transaminase (AST) and alanine transaminase (ALT) values., Accordingly, in clinical settings, to detect NAFLD, measurement of aminotransferases, blood lipids, and insulin resistance (IR) are often used., Several indicators such as lipid profile, AST, ALT, fasting blood sugar (FBS), CRP, and fasting insulin level play a significant role in NAFLD. These indicators assist in understanding the severity and prognosis of the disease, and also results in early intervention, which is a good alternative to liver biopsy.,
This study aimed to determine biochemical markers and lipid profile in patients with and without NAFLD, and also examine their possible relationship with degrees of NAFLD.
| Methods|| |
In this analytical-cross-sectional study, 950 individuals aged 35–60 years referred to the PERSIAN Guilan Cohort Study (PGCS), part of the Prospective Epidemiological Research Studies in Iran (The PERSIAN Cohort Study) (from April 2017 to September 2017), were included through sequential sampling method. Not having chronic and acute liver disease including viral hepatitis C, B, chronic or acute kidney disease, cancers, alcohol consumption (men, more than 20 g/day, and women, more than 10 g/day), pregnancy, taking medications affecting the liver such as steroids, amiodarone, tamoxifen, and patients with proven hemochromatosis, were considered as the exclusion criteria for this study, and identification of the subjects was conducted based on the file created in the cohort plan.
After receiving consent form and explaining the research objectives, the personal information of the subjects (age, gender, and level of education, occupation, place of residence, marital status and smoking) was completed face-to-face. Blood pressure (mmHg) was measured by cuff pressure gauge (MTM Munich, Germany) and based on the PERSIAN cohort protocol. Systolic blood pressure equal to or above 140 mmHg or diastolic blood pressure equal to or above 90 mmHg were considered as hypertension.
Venous blood sample was taken from all participants after 12 h of fasting, and then sent to the laboratory of the unit on the same day. Parameters including hepatic enzymes such as aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), and gamma-glutamy ltransferase (GGT) as well as the lipid profile including triglyceride (TG), total cholesterol (TC), high density lipoprotein cholesterol (HDL-C), low-density lipoprotein cholesterol (LDL-C), and fasting blood sugar (FBS) were examined by quantitative diagnostic kit (Parsazmoon Co., Tehran, Iran) and investigated through photometric method. Abdominal ultrasonography was performed by ultrasonix device from sonix SP series using a deep probe of 3.5-5 MHz to detect fatty liver and confirmed by two radiologists residing in the cohort center. Based on the sonography findings, fatty liver was categorized into three grades: Grade 1 (mild): elevated echogenicity of liver paranchyma with visible periportal and diaphragm; Grade 2 (moderate): elevated echogenicity of liver paranchyma with obstruction of the walls of the portal vein branches, without diaphragm blockage; Grade 3 (severe): elevated echogenicity of liver paranchyma with undetectable periportal echogenicity and diaphragm obstruction. The subjects in this study were considered as NAFLD group with any degree and severity of liver disease.
For all analyses, SPSS 18 was used. The numerical variables were expressed as mean ± standard deviation (SD), while the classification variables were expressed by number (%). Statistical analysis was done by independent sample t-test, one-way ANOVA and logistic regression model. P value less than 0.05 was considered significant.
This study has been registered in the committee of research and ethics of the Research Center for Gastroenterology and Hepatology of Guilan University of Medical Sciences (registration code: IR.GUMS.REC.1394.499). Written consent form was obtained from all the subjects and at any stage of the research, they were free to withdraw from the study.
| Results|| |
Of 950 cases, 587 (61.8%) were female, out of which 154 (42.4%) had NAFLD. The minimum age was 35 and the maximum was 60 years, and 382 (40.2%) were within the age range of 35-44 years. The demographic information of the subjects per NAFLD and non-NAFLD is reported in [Table 1].
In this study, the mean age of the subjects was 47.14 ± 7.2 years, and the mean FBS, systolic blood pressure (SBP), and diastolic blood pressure (DBP) was 102.59 ± 31.7, 120.62 ± 16.84 and 80.70 ± 11.35, respectively. The total mean of the results of lipid profile and level of hepatic enzymes is presented in [Table 2].
The results of this study showed no significant relationship between age and NAFLD (P = 0.34, OR: 1.009; 95% CI: 0.991-1.026). In the NAFLD group, the mean values of TG, GGT, AST, ALT, ALP, and TC were higher, while that of HDL was lower than those of non-NAFLD [Table 3].
|Table 3: The values of assessed clinical and laboratory data (expressed as±SD) of subjects NAFLD and Non- NAFLD|
Click here to view
The results of this study showed that with elevation of SBP, DBP, FBS, TC, LDL/HDL ratio, TC/HDL ratio, AST/ALT ratio, GGT, ALT, and AST (OR >1), and reduction of HDL (OR <1), the possibility of developing NAFLD increased, whereby, a significant relationship was observed (P < 0.05). However, the level of LDL (121.82 ± 32.50 vs. 121.10 ± 29.71; OR: 0.999; 95% CI: 0.995-1.003) and ALP (196.01 ± 53.71 vs. 192.00 ± 56.92; OR: 1.001; 95% CI: 0.999-1.004) was not significant between the groups [Table 3].
When the changes in biochemical parameters were compared with different degrees of NAFLD, the research results showed that there was a relationship between GGT (P = 0.004), ALT (P = 0.007) and AST (P < 0.001), and the severity of fatty liver [Table 4].
|Table 4: Correlation of biochemical parameters with severity of ultrasound-based grading of NAFLD|
Click here to view
| Discussion|| |
Since NAFLD does not have any special clinical sign and is a silent disease, this study tries to express the relationship between clinical together with laboratory signs, and NAFLD.
As reported by Pardhe et al., there is no significant relationship between age and NAFLD. Similarly, Uppalapti et al. provided results in a study on diabetic patients, which is in line with the current study. However, Navokovic et al. and Swain et al. reported that there is a significant relationship between age and NAFLD.
Dyslipidemia is known as a risk factor for NAFLD. In this study, individuals in the NAFLD group had a higher TC, LDL/HDL ratio and TC/HDL ratio and lower HDL as compared to those in the non-NAFLD group. Further, in the NAFLD group, a significant relationship was observed with TG, but no significant relationship was seen between LDL and NAFLD. In a study conducted by Santhoshakumari et al., patients with NAFLD had higher TC, LDL, and TG, and lower HDL as compared to the control group, and in this study, dyslipidemia was significantly higher in the NAFLD group. In another study, again, mean LDL, and TC was higher than the normal range among NAFLD subjects. Further, Novakovic et al. in Serbia, compared chemical parameters with NAFLD and found that there is a significant relationship between TG, LDL, TC, and HDL, and an inverse relationship with HDL in the group. The study by Pardhe  as well as Jain et al. indicated similar results.
In the present study, the mean DBP and SBP in the NAFLD group was higher than that of non-NAFLD group, where individuals with higher systolic and diastolic blood pressure indicated higher risk for developing NAFLD, and a significant relationship was observed between BP and NAFLD. This result is in accordance with the findings of a number of studies.,,,
The present study showed that with elevation of FBS level, the possibility of developing NAFLD increases (OR = 1.013, CI: 1.008-1.018), and there is a significant relationship between them. Studies by Jain et al., Novakovic et al. and Pardhe et al. also confirmed this finding.
In this study, the mean levels of hepatic enzymes were higher in the NAFLD group, and apart from ALP (P = 0.26), in other cases, a significant relationship was observed with NAFLD. In the study of Novakovic et al. a significant relationship was observed between hepatic enzymes (ALT, GGT, AST/ALT ratio) apart from AST and NAFLD. Most previous studies have shown that there is a significant relationship between NAFLD and AST,, ALT ,, and ALP. Zakeri and Karmarat-Panah  stated that ALT and dyslipidemia might be involved in the prevalence and development of NAFLD.
For preliminary diagnosis of NAFLD, ultrasonography can be used. It can be posited that sonography with the minimum cost and complications is the cheapest method for identifying NAFLD-associated changes. In this study, a significant relationship was observed between hepatic enzymes GGT (P = 0.004), ALT (P < 0.001), AST (P < 0.001) and NAFLD degrees. In a report by Cuenza et al. in Philippine, investigation of FL degrees through sonography indicated that AST (P = 0.00), ALT (P = 0.001), TG (0.047) and FBS (P = 0.049) had a relationship with NAFLD grades, though it did not have any relationship with age, LDL, HDL and TG. Further, Mahaling et al. showed increased degrees of NAFLD with elevation of TC (P = 0.001), LDL (P = 0.000) and VLDL (P = 0.003), and reduction of HDL (P = 0.000), but no significant relationship was observed between TG (P = 0.05) and NAFLD degrees. The study by Pardhe et al. in Nepal showed a significant relationship between hepatic enzymes (ALT, ALP) and dyslipidemia (TG, HDL), and different grades of NAFLD.
The limitation of this study was the use of ultrasonography to detect NAFLD. Liver biopsy is a golden standard for diagnosing fatty liver, but because of its invasiveness, risk of complications, and high cost, it is not recommended for the general population. On the other hand, abdominal ultrasonography is a noninvasive, low risk, simple, relatively low-cost and easily available method. In this study, to control this limitation, the comments of two radiologists were used concurrently.
| Conclusion|| |
The results of this study indicated that in patients with NAFLD, there are considerable changes in biochemical markers. Thus, it seems essential that in clinical settings in cases in which biochemical and lipid changes are observed, sonography should be performed to examine individuals with NAFLD, since early diagnosis prevents further complications and delays them.
This paper is part of a PhD thesis in Gastrointestinal and Liver Diseases Research Center (GLDRC). The authors highly appreciate all the participants of this study as well as the PERSIAN Guilan cohort study and Gastrointestinal and Liver Diseases Research Center at Guilan University of Medical Sciences, Rasht, Iran.
Financial support and sponsorship
Conflicts of interest
There are no conflicts of interest.
| References|| |
Ahmed M. Non-alcoholic fatty liver disease in 2015. World J Hepatol 2015;7:1450-9.
Jain P, Parate R, Dubey T, Jain R. Prevalence of NAFLD (non-alcoholic fatty liver disease) in metabolic syndrome and their correlation with various biochemical and serologic parameters for early detection and detecting patients of lean Nash (Non-alcoholic steatohepatitis). Prevalence 2018;3:24-8.
LaBrecque DR, Abbas Z, Anania F, Ferenci P, Khan AG, Goh K-L, et al
. World Gastroenterology Organisation global guidelines: Nonalcoholic fatty liver disease and nonalcoholic steatohepatitis. Journal of Clinical Gastroenterology 2014;48:467-73.
Araújo AR, Rosso N, Bedogni G, Tiribelli C, Bellentani S. Global epidemiology of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis: What we need in the future. Liver Int 2018;38:47-51.
Chun-Jen L. Prevalence and risk factors for non-alcoholic fatty liver disease in Asian people who are not obese. J Gastroenterol Hepatol 2012;27:1555-60.
Bellentani S, Scaglioni F, Marino M, Bedogni G. Epidemiology of non-alcoholic fatty liver disease. Dig Dis 2010;28:155-61.
Lankarani KB, Ghaffarpasand F, Mahmoodi M, Lotfi M, Zamiri N, Heydari ST, et al
. Non alcoholic fatty liver disease in southern Iran: A population based study. Hepat Mon 2013;13:e9248.
Moghaddasifar I, Lankarani K, Moosazadeh M, Afshari M, Ghaemi A, Aliramezany M, et al
. Prevalence of non-alcoholic fatty liver disease and its related factors in Iran. Int J Organ Transplant Med 2016;7:149-60.
McLernon DJ, Donnan PT, Sullivan FM, Roderick P, Rosenberg WM, Ryder SD, et al
. Prediction of liver disease in patients whose liver function tests have been checked in primary care: Model development and validation using population-based observational cohorts. BMJ Open 2014;4:e004837.
Swain M, Nath P, Parida PK, Narayan J, Padhi PK, Pati GK, et al
. Biochemical profile of nonalcoholic fatty liver disease patients in eastern India with histopathological correlation. Indian J Clin Biochem 2017;32:306-14.
Anderson EL, Howe LD, Jones HE, Higgins JP, Lawlor DA, Fraser A. The prevalence of non-alcoholic fatty liver disease in children and adolescents: A systematic review and meta-analysis. PloS One 2015;10:e0140908.
Alterio A, Alisi A, Liccardo D, Nobili V. Non-alcoholic fatty liver and metabolic syndrome in children: A vicious circle. Horm Res Paediatr 2014;82:283-9.
Das K, Das K, Mukherjee PS, Ghosh A, Ghosh S, Mridha AR, et al
. Nonobese population in a developing country has a high prevalence of nonalcoholic fatty liver and significant liver disease. Hepatology 2010;51:1593-602.
Poustchi H, Eghtesad S, Kamangar F, Etemadi A, Keshtkar A-A, Hekmatdoost A, et al
. Prospective epidemiological research studies in Iran (the PERSIAN cohort study): Rationale, objectives, and design. Am J Epidemiol 2017;187:647-55.
Aneni EC, Oni ET, Martin SS, Blaha MJ, Agatston AS, Feldman T, et al
. Blood pressure is associated with the presence and severity of nonalcoholic fatty liver disease across the spectrum of cardiometabolic risk. Journal of Hypertension 2015;33:1207-14.
Pardhe BD, Shakya S, Bhetwal A, Mathias J, Khanal PR, Pandit R, et al
. Metabolic syndrome and biochemical changes among non-alcoholic fatty liver disease patients attending a tertiary care hospital of Nepal. BMC Gastroenterol 2018;18:109.
Uppalapati GP, Harish K. A study of clinical, biochemical and sonological profile of non-alcoholic fatty liver disease in type 2 diabetes patients. J Evid Based Med Healthc 2017;4:5414-7.
Novakovic T, Mekic M, Smilic L, Smilic T, Inić-Kostic B, Jovicevic L, et al
. Anthropometric and biochemical characteristics of patients with nonalcoholic fatty liver diagnosed by non-invasive diagnostic methods. Med Arch 2014;68:22-6.
Santhoshakumari TMJ, Radhika G, Kanagavalli P. A study of anthropometric and lipid profile parameters in non-alcoholic fatty liver disease patients attending a tertiary care hospital at puducherry. IOSR J Dent Med Sci (IOSR-JDMS) 2017;16:33-7.
Cuenza LR, Razon TLJ, Dayrit JC. Correlation between severity of ultrasonographic nonalcoholic fatty liver disease and cardiometabolic risk among Filipino wellness patients. J Cardiovasc Thorac Res 2017;9:85-9.
Zakeri A, Karamat-Panah S. Prevalence of non-alcoholic fatty liver disease and its risk factors in patients referred to Ardabil city hospital during 2015-2016. Int J Community Med Pub Health 2018;5:917-21.
Mahaling DU, Basavaraj MM, Bika AJ. Comparison of lipid profile in different grades of non-alcoholic fatty liver disease diagnosed on ultrasound. Asian Pac J Trop Biomed 2013;3:907-12.
[Table 1], [Table 2], [Table 3], [Table 4]
|This article has been cited by|
||Silymarin in Combination with Vitamin C, Vitamin E, Coenzyme Q10 and Selenomethionine to Improve Liver Enzymes and Blood Lipid Profile in NAFLD Patients
| ||Annalisa Curcio,Adriana Romano,Simona Cuozzo,Antonio Di Nicola,Orazio Grassi,Donatella Schiaroli,Giuseppe Fabrizio Nocera,Michele Pironti |
| ||Medicina. 2020; 56(10): 544 |
|[Pubmed] | [DOI]|
||Non-alcoholic fatty liver disease and transient elastography
| ||Ivana Mikolasevic,Andela Lukic,Toni Juric,Mia Klapan,Petra Madzar,Nikola Krolo,Doris Kolovrat,Ivanka Jurica,Iva Kedmenec,Domagoj Kihas,Doris Ilovaca,Ivan Erstic,Vanda Haralovic,Danijel Cavlina,Ema Dejhalla,Danijela Erdeljac,Benjamin Vukalovic,Nadija Skenderevic,Sandra Milic |
| ||Exploration of Medicine. 2020; 1(4): 205 |
|[Pubmed] | [DOI]|
||Regression of Nonalcoholic Fatty Liver Disease Detected by Sonography: Results of a Four Years Prospective Adult Population-based Study
| ||Parisa Keshani,Kamran Bagheri Lankarani,Behnam Honarvar,Hadi Raeisi Shahraki |
| ||Hepatitis Monthly. 2019; In Press(In Press) |
|[Pubmed] | [DOI]|
||Metabolomic Biomarkers in the Diagnosis of Non-Alcoholic Fatty Liver Disease
| ||Saeed Chashmniam,Mohsen Ghafourpour,Azam Rezaei,Ali Gholami,Bibi Fatemeh Nobakht Motlagh Ghoochani |
| ||Hepatitis Monthly. 2019; In Press(In Press) |
|[Pubmed] | [DOI]|